Nelson Vergel
Founder, ExcelMale.com
Orexigen Therapeutics has announced that encouraging interim results from the Light Study evaluating the cardiovascular risks of combination naltrexone/bupropion, indicated for weight loss in obese patients, have prompted resubmission of a new drug application to the FDA., according to a press release.
http://www.healio.com/endocrinology...pion-interim-data-yield-favorable-cv-outcomes
http://www.healio.com/endocrinology...pion-interim-data-yield-favorable-cv-outcomes